These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16218405)

  • 1. [Roles of BPH impact index in the evaluation of impaired urination in patients with BPH].
    Ikemoto I; Kiyota H; Suzuki Y; Oishi Y; Kishimoto K; Shimomura T; Yamada H; Torii S; Shirai T; Takeuchi H; Abe K; Egawa S
    Nihon Hinyokika Gakkai Zasshi; 2005 Sep; 96(6):623-31. PubMed ID: 16218405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.
    Angalakuditi M; Seifert RF; Hayes RP; O'Leary MP; Viktrup L
    Health Qual Life Outcomes; 2010 Nov; 8():131. PubMed ID: 21073697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
    Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
    Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin Administration.
    Gotoh M; Matsukawa Y; Funahashi Y; Kato M; Maseki Y; Narita H; Kamihira O; Hattori R
    Low Urin Tract Symptoms; 2012 Jan; 4(1):45-50. PubMed ID: 26676459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between lower urinary tract symptoms and health status: the UREPIK study.
    Boyle P; Robertson C; Mazzetta C; Keech M; Hobbs R; Fourcade R; Kiemeney L; Lee C;
    BJU Int; 2003 Oct; 92(6):575-80. PubMed ID: 14511037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being.
    Eckhardt MD; van Venrooij GE; van Melick HH; Boon TA
    J Urol; 2001 Aug; 166(2):563-8. PubMed ID: 11458069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
    Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
    Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seasonal changes in symptom score and uroflowmetry in patients with lower urinary tract symptoms.
    Watanabe T; Maruyama S; Maruyama Y; Kageyama S; Shinbo H; Otsuka A; Ozono S
    Scand J Urol Nephrol; 2007; 41(6):521-6. PubMed ID: 17853015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient.
    Kingery L; Martin ML; Naegeli AN; Khan S; Viktrup L
    Int J Clin Pract; 2012 Sep; 66(9):883-90. PubMed ID: 22897465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom-specific quality of life in patients with benign prostatic hyperplasia.
    Yoshimura K; Arai Y; Ichioka K; Terada N; Matsuta Y; Okubo K
    Int J Urol; 2002 Sep; 9(9):485-90. PubMed ID: 12410928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    van Venrooij GE; van Melick HH; Eckhardt MD; Boon TA
    Urology; 2008 Mar; 71(3):469-74. PubMed ID: 18342189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.
    Barry MJ; Fowler FJ; O'Leary MP; Bruskewitz RC; Holtgrewe HL; Mebust WK
    Med Care; 1995 Apr; 33(4 Suppl):AS145-55. PubMed ID: 7536866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
    Lyauk YK; Lund TM; Hooker AC; Karlsson MO; Jonker DM
    AAPS J; 2020 Jul; 22(5):98. PubMed ID: 32728925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.